Rodrigo Carrasco

Dr. Rodrigo Carrasco

Department of Cardiology, University Heart Center., University Hospital Zurich (USZ), Zürich, Switzerland
orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2013 in CNS & Neurological Disorders - Drug Targets
Verified
Journal Article
Closed access
PDF file
RRRamón Rodrigo
Ramón Rodrigo
RFRodrigo Fernandez-Gajardo
Rodrigo Fernandez-Gajardo
RGRodrigo Gutierrez
Rodrigo Gutierrez
JMJose Manuel Matamala
Jose Manuel Matamala
Rodrigo CarrascoRodrigo Carrasco
Rodrigo Carrasco
WFWalter Feuerhake
Walter Feuerhake
Stroke is the second leading cause of death, after ischemic heart disease, and accounts for 9% of deaths worldwide. According to the World Health Organization [WHO], 15 million people suffer stroke worldwide each year. Of these, more than 6 million die and another 5 million are permanently disabled. Reactive oxygen species [ROS] have been implicated in brain injury after ischemic stroke. There is evidence that a rapid increase in the production of ROS immediately after acute ischemic stroke rapidly overwhelm antioxidant defences, causing further tissue damage. These ROS can damage cellular macromolecules leading to autophagy, apoptosis, and necrosis. Moreover, the rapid restoration of blood flow increases the level of tissue oxygenation and accountsfor a second burst of ROS generation, which leads to reperfusion injury. Current measures to protect the brain against severe stroke damage are insufficient. Thus, it is critical to investigate antioxidant strategies that lead to the diminution of oxidative injury. The antioxidant vitamins C and E, the polyphenol resveratrol, the xanthine oxidase [XO] inhibitor allopurinol, and other antioxidant strategies have been reviewed in the setting of strokes. This review focuses on the mechanisms involved in ROS generation, the role of oxidative stress in the pathogenesis of ischemic stroke, and the novel therapeutic strategies to be tested to reduce the cerebral damage related to both ischemia and reperfusion.

1 September 2017 in Nutrients
Verified
Journal Article
Open access
PDF file
Jorge G. FaríasJorge G. Farías
Jorge G. Farías
VMVíctor M. Molina
Víctor M. Molina
Rodrigo CarrascoRodrigo Carrasco
Rodrigo Carrasco
AZAndrea B. Zepeda
Andrea B. Zepeda
EVElías Figueroa Villalobos
Elías Figueroa Villalobos
RCRodrigo Castillo
Rodrigo Castillo
Oxidative stress (OS) refers to the imbalance between the generation of reactive oxygen species (ROS) and the ability to scavenge these ROS by endogenous antioxidant systems, where ROS overwhelms the antioxidant capacity. Excessive presence of ROS results in irreversible damage to cell membranes, DNA, and other cellular structures by oxidizing lipids, proteins, and nucleic acids. Oxidative stress plays a crucial role in the pathogenesis of cardiovascular diseases related to hypoxia, cardiotoxicity and ischemia–reperfusion. Here, we describe the participation of OS in the pathophysiology of cardiovascular conditions such as myocardial infarction, anthracycline cardiotoxicity and congenital heart disease. This review focuses on the different clinical events where redox factors and OS are related to cardiovascular pathophysiology, giving to support for novel pharmacological therapies such as omega 3 fatty acids, non-selective betablockers and microRNAs.

1 October 2013 in JACC
Verified
Journal Article
Closed access
RRRamón Rodrigo
Ramón Rodrigo
PKPanagiotis Korantzopoulos
Panagiotis Korantzopoulos
MCMauricio Cereceda
Mauricio Cereceda
RARené Asenjo
René Asenjo
JZJaime Zamorano
Jaime Zamorano
JGJuan G. Gormaz
Juan G. Gormaz

2 May 2023 in JACC: Cardiooncology
Verified
Journal Article
Open access
HAHusam Abdel-Qadir
Husam Abdel-Qadir
Rodrigo CarrascoRodrigo Carrasco
Rodrigo Carrasco
PAPeter C. Austin
Peter C. Austin
YCYue Chen
Yue Chen
LZLimei Zhou
Limei Zhou
PTPaaladinesh Thavendiranathan
Paaladinesh Thavendiranathan
Sodium glucose cotransporter-2 inhibitors (SGLT2is) are hypothesized to reduce the risk of anthracycline-associated cardiotoxicity. This study sought to determine the association between SGLT2is and cardiovascular disease (CVD) after anthracycline-containing chemotherapy. Using administrative data sets, we conducted a population-based cohort study of people >65 years of age with treated diabetes and no prior heart failure (HF) who received anthracyclines between January 1, 2016, and December 31, 2019. After estimating propensity scores for SGLT2i use, the average treatment effects for the treated weights were used to reduce baseline differences between SGLT2i-exposed and -unexposed controls. The outcomes were hospitalization for HF, incident HF diagnoses (in- or out-of-hospital), and documentation of any CVD in future hospitalizations. Death was treated as a competing risk. Cause-specific HRs for each outcome were determined for SGLT2i-treated people relative to unexposed controls. We studied 933 patients (median age 71.0 years, 62.2% female), 99 of whom were SGLT2i treated. During a median follow-up of 1.6 years, there were 31 hospitalizations for HF (0 in the SGLT2i group), 93 new HF diagnoses, and 74 hospitalizations with documented CVD. Relative to controls, SGLT2i exposure was associated with HR of 0 for HF hospitalization (P < 0.001) but no significant difference in incident HF diagnosis (HR: 0.55; 95% CI: 0.23-1.31; P = 0.18) or CVD diagnosis (HR: 0.39; 95% CI: 0.12-1.28; P = 0.12). There was no significant difference in mortality (HR: 0.63; 95% CI: 0.36-1.11; P = 0.11). SGLT2is may reduce the rate of HF hospitalization after anthracycline-containing chemotherapy. This hypothesis warrants further testing in randomized controlled trials.

28 February 2020 in Frontiers in Pharmacology
Verified
Journal Article
Open access
RCRodrigo Castillo
Rodrigo Castillo
MIMauricio Ibacache
Mauricio Ibacache
ICIgnacio Cortínez
Ignacio Cortínez
Catalina Carrasco-PozoCatalina Carrasco-Pozo
Catalina Carrasco-Pozo
Jorge G. FaríasJorge G. Farías
Jorge G. Farías
AMAníbal Méndez
Aníbal Méndez
Dexmedetomidine (DEX) is a highly selective α2-adrenergic agonist with sedative and analgesic properties, with minimal respiratory effects. It is used as a sedative in the intensive care unit, the operating room, and occasionally in other locations. The opioid-sparing effect and the absence of respiratory effects make dexmedetomidine an attractive adjuvant drug for anesthesia in obese patients who are at an increased risk for postoperative respiratory complications. The pharmacodinamic effects on the cardiovascular system are known, however the mechanisms that induce cardioprotection are still under study. Regarding the pharmacokinetics properties, this drug is extensively metabolized in the liver by the uridine diphosphate glucuronosyltransferases. It has a relatively high hepatic extraction ratio, and therefore, its metabolism is dependent on liver blood flow. This review shows, from a basic clinical approach, the evidence supporting the use of dexmedetomidine in different settings, from the use in animal models of ischemia-reperfusion and cardioprotective signaling pathways. Pharmacokinetics and pharmacodynamics studies in obese subjects and the management of patients subjected to mechanical ventilation for avoiding the deleterious of sedation. Moreover, the clinical efficacy in patients with indication of non-invasive ventilation, and the lower incidence of delirium when compared with other sedatives. The evidence described about dexmedetomidine brings a group of Chilean pharmacologists and clinicians, who have worked for more than 10 years on the subject of α2-adrenergic agonists and support independent lines of research, both in animal models and in clinical practice with patients.

27 January 2021 in Oxidative Medicine and Cellular Longevity
Verified
Journal Article
Open access
PDF file
Rodrigo CarrascoRodrigo Carrasco
Rodrigo Carrasco
RCRodrigo Castillo
Rodrigo Castillo
JGJuan G. Gormaz
Juan G. Gormaz
MCMontserrat Carrillo
Montserrat Carrillo
PTPaaladinesh Thavendiranathan
Paaladinesh Thavendiranathan
Anthracycline‐induced cardiotoxicity (AIC) persists as a significant cause of morbidity and mortality in cancer survivors. Although many protective strategies have been evaluated, cardiotoxicity remains an ongoing threat. The mechanisms of AIC remain unclear; however, several pathways have been proposed, suggesting a multifactorial origin. When the central role of topoisomerase 2β in the pathophysiology of AIC was described some years ago, the classical reactive oxygen species (ROS) hypothesis shifted to a secondary position. However, new insights have reemphasized the importance of the role of oxidative stress‐mediated signaling as a common pathway and a critical modulator of the different mechanisms involved in AIC. A better understanding of the mechanisms of cardiotoxicity is crucial for the development of treatment strategies. It has been suggested that the available therapeutic interventions for AIC could act on the modulation of oxidative balance, leading to a reduction in oxidative stress injury. These indirect antioxidant effects make them an option for the primary prevention of AIC. In this review, our objective is to provide an update of the accumulated knowledge on the role of oxidative stress in AIC and the modulation of the redox balance by potential preventive strategies.